Teva Pharmaceuticals Launches Generic Octreotide Acetate for Injectable Suspension
Key Insights
Teva Pharmaceuticals has launched the first generic version of Sandostatin LAR Depot in the U.S., offering a new treatment option.
The generic octreotide acetate is indicated for treating acromegaly (search) and severe diarrhea associated with carcinoid syndrome (search).
Sandostatin LAR Depot, the branded version, recorded annual sales of $826 million as of July 2024, indicating a substantial market.
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, has announced the launch of its generic version of Sandostatin LAR Depot (octreotide acetate for injectable suspension) in the United States. This marks the availability of the first and only generic equivalent to this important medication.
The newly launched octreotide acetate is indicated for the treatment of acromegaly (search), a hormonal disorder that develops when the pituitary gland produces too much growth hormone, and for managing severe diarrhea associated with carcinoid syndrome (search), a condition caused by tumors that secrete certain chemicals into the bloodstream.
"With today's launch of octreotide acetate for injectable suspension, Teva is providing patients a new option for this important treatment," said Ernie Richardsen, SVP U.S. Commercial Generics.
The introduction of a generic alternative to Sandostatin LAR Depot is significant, considering the branded drug's substantial market presence. Sandostatin LAR Depot recorded annual sales of $826 million as of July 2024. The availability of a generic version is expected to provide a more cost-effective option for patients requiring this treatment, potentially increasing access to this essential medication. The drug is administered via injection.